CSO Ranga Sarangarajan, CAO Slava Akmaev explain how embrace of AI has led to promising drug candidates.

PharmaLetter_Logo_696

CSO Ranga Sarangarajan, CAO Slava Akmaev explain how Berg’s embrace of AI has led to the development of promising drug candidates BPM 31510 and BPM-31543.

Sarangarajan notes that “AI provides an opportunity for understanding the data in avenues that a traditionally trained mind can’t. We have our biases, but AI is purely data-driven.”

Read the article.